ARCTIC BIOSCIENCE
Research ARCTIC BIOSCIENCE (ABS.OL) on Bullrun: market cap NOK 71.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABS.OL
- ExchangeMERK
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 71.16M
- Financial periodFY2025
- RevenueNOK 40.10M
- Revenue growth-7.8%
- Net income-NOK 41.03M
- Free cash flow-NOK 45.40M
- Gross margin27.5%
Valuation Snapshot
latest market cap is NOK 71.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 40.10M | -NOK 41.03M | -NOK 45.40M | 27.5% | -1.52 | NOK 218.12K | NOK 63.34M | NOK 173.49M |
| FY2024 | NOK 43.48M | -NOK 47.93M | -NOK 96.17M | 27.3% | -1.89 | NOK 2.16M | NOK 31.38M | NOK 210.73M |
| FY2023 | NOK 33.75M | -NOK 45.51M | -NOK 65.07M | 29.0% | -1.79 | NOK 78.47M | NOK 5.58M | NOK 258.56M |
| FY2022 | NOK 34.27M | -NOK 34.02M | -NOK 83.96M | 34.0% | -1.39 | NOK 143.16M | NOK 1.10M | NOK 287.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-10 | NOK 71.16M | n/a | n/a | n/a |
About ARCTIC BIOSCIENCE
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ARCTIC BIOSCIENCE's market cap?
ARCTIC BIOSCIENCE's market capitalization is NOK 71.16M.
What does ARCTIC BIOSCIENCE do?
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name.